The prevalence of bcl-2, p53, and ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates
- 1 February 1998
- journal article
- Published by Elsevier in Human Pathology
- Vol. 29 (2) , 146-154
- https://doi.org/10.1016/s0046-8177(98)90225-8
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Bcl-2 expression and its association with cell kinetics in human gastric carcinomas and intestinal metaplasiaZeitschrift für Krebsforschung und Klinische Onkologie, 1995
- Bcl-2 and the regulation of programmed cell deathThe Journal of cell biology, 1994
- bcl-2 Protein in Non-Small-Cell Lung CarcinomaNew England Journal of Medicine, 1993
- p53, guardian of the genomeNature, 1992
- Progression and survival in transitional cell bladder cancer: a comparison of established prognostic factors, S-phase fraction and DNA ploidyEuropean Journal of Cancer and Clinical Oncology, 1991
- Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6Nature, 1991
- Programmed cell death: Apoptosis and oncogenesisCell, 1991
- bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferationCell, 1989
- Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cellsNature, 1988
- Involvement of the bcl -2 Gene in Human Follicular LymphomaScience, 1985